Free Trial

Agios Pharmaceuticals Q3 2023 Earnings Report

Agios Pharmaceuticals logo
$27.40 -1.90 (-6.48%)
As of 04:00 PM Eastern

Agios Pharmaceuticals EPS Results

Actual EPS
-$1.64
Consensus EPS
-$1.69
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Agios Pharmaceuticals Revenue Results

Actual Revenue
$7.40 million
Expected Revenue
$7.73 million
Beat/Miss
Missed by -$330.00 thousand
YoY Revenue Growth
N/A

Agios Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

Agios Pharmaceuticals Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Agios Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agios Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agios Pharmaceuticals and other key companies, straight to your email.

About Agios Pharmaceuticals

Agios Pharmaceuticals (NASDAQ:AGIO), a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

View Agios Pharmaceuticals Profile

More Earnings Resources from MarketBeat